Sofgen Pharma S.A PROCF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $114.0M
- P/E
- 0.0×
Follow PROCF
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
17.37 | 7.17 | 7.81 | 10.54 |
P/S ratio |
1.14 | 1.09 | 0.89 | 1.02 | |
P/FCF ratio |
0.00 | 0.00 | 11.34 | 5.78 | |
P/Operating CF |
146.72 | 21.28 | 7.65 | 11.78 | |
P/B ratio |
88.22 | 13.57 | 9.43 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.80 | 1.77 | 1.55 | 1.72 | |
EV/EBITDA |
26.02 | 29.29 | 30.13 | 8.08 | |
EV/Operating CF |
58.54 | 31.02 | 9.79 | 6.77 | |
EV/FCF |
(34.43) | (74.98) | 19.72 | 9.74 | |
Quick Ratio |
0.60 | 0.64 | 0.83 | 0.34 | |
Current Ratio |
1.15 | 1.21 | 1.47 | 0.64 | |
Net Debt/EBITDA |
38.03 | 14.03 | 14.77 | 6.49 | |
Debt/Assets |
65.30% | 59.55% | 58.98% | 67.88% | |
Debt/Equity |
55.80 | 9.12 | 7.65 | (435.78) | |
Asset Turnover |
0.87 | 0.83 | 0.84 | 0.93 | |
Operating CF/Net income |
0.47 | 0.76 | 5.78 | (25.72) | |
Capex/Depreciation |
(1.31) | (1.82) | (1.54) | (2.39) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
50.84% | 41.89% | 46.63% | 44.31% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.37) | (0.38) | (0.45) | (0.46) | |
Graham Number |
0.55 | 2.07 | 1.98 | 0.00 | |
Earnings Yield |
5.76% | 13.95% | 12.81% | 9.49% | |
Free Cash Flow Yield |
(4.60%) | (2.17%) | 8.82% | 17.31% | |
Revenue per Share |
0.83 | 1.09 | 1.17 | 1.10 | |
Operating CF per Share |
0.03 | 0.20 | 0.47 | 0.36 | |
Capex per Share |
(0.05) | (0.08) | (0.08) | (0.12) | |
Free Cash Flow per Share |
(0.02) | 0.12 | 0.39 | 0.24 | |
Cash per Share |
0.23 | 0.20 | 0.26 | 0.24 | |
Shareholders Equity per Share |
0.05 | 0.32 | 0.38 | (0.01) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.05 | 0.32 | 0.38 | (0.01) | |
Free Cash Flow |
(1.76) | 12.57 | 39.71 | 24.31 | |
Working Capital |
35.38 | 51.67 | 95.42 | (157.92) | |
Capital Expenditures |
(4.86) | (7.86) | (7.68) | (12.39) | |
Net Current Asset Value |
(167.70) | (163.14) | (161.75) | (197.59) | |
EV/EBIT |
67.57 | 92.52 | 181.32 | 10.12 | |
Capex to Sales |
0.06 | 0.07 | 0.06 | 0.11 | |
Net Profit Margin |
7.87% | 24.49% | 6.92% | (1.28%) | |
Price to Operating Income |
42.71 | 56.89 | 104.25 | 6.00 | |
| Other line items | |||||
Average Receivables |
113.96 | 128.37 | 136.17 | 115.64 | |
Average Payables |
75.04 | 88.28 | 92.52 | — | |
Average Inventory |
98.75 | 101.35 | 99.30 | 100.79 | |
Average Assets |
462.49 | 480.46 | 484.86 | 457.51 | |
Average Common Equity |
(7.24) | 1.23 | 13.97 | (18.93) |
Columns are period end dates